T1	HMM 471 497	antitumor activity of TMZ.
T2	HMM 1062 1077	Tumor responses
T3	HMM 1187 1219	median time to progression (TTP)
T4	HMM 1273 1301	median overall survival (OS)
T5	HMM 1399 1435	objective response rates, TTP and OS
T6	HMM 1521 1619	anemia, leukopenia, neutropenia, thrombocytopenia, fatigue, constipation and arthralgias/myalgias.
T7	HMM 1649 1669	grade 3 and 4 emesis
T8	HMM 1706 1722	No clear benefit
T9	HMM 1735 1761	response rates, median TTP
T10	HMM 1884 1905	grade 3 and 4 emesis.
